Sundrug stock: J.P. Morgan keeps Hold rating ahead of results
Published on 11/11/2026 at 01:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSJ.P. Morgan maintains a cautious stance
- J.P. Morgan kept its Hold rating on Sundrug on November 4, 2026.
- The bank set a price target of 4,100 Japanese yen.
- Sundrug reported quarterly revenue of 215.33 billion Japanese yen for the period ended June 30.
J.P. Morgan kept its Hold rating on Sundrug on November 4, 2026, and set a price target of 4,100 Japanese yen. Markets Insider reported the analyst decision through TipRanks.
Analyst view stays measured
The rating leaves J.P. Morgan on the sidelines rather than signaling a fresh bullish call. The 4,100-yen target provides a reference point for investors assessing Sundrug's prospects after its latest quarterly update.
Sundrug reported revenue of 215.33 billion Japanese yen and net profit of 8.02 billion Japanese yen for the quarter ended June 30. In the comparable period, revenue was 207.7 billion Japanese yen and net profit was 7.94 billion Japanese yen, according to the Markets Insider report.
Sundrug company profile
- Company: Sundrug Co., Ltd.
- ISIN: JP3336600006
- Ticker: 9989.T
- Home market: Tokyo Stock Exchange
- Business: Japanese drugstore and retail network focused on health, convenience and low-cost operations
Japanese equities offer the broader market context for investors following Nikkei 225 market developments.
For further company coverage, see More news and analyses on Sundrug stock.
